A pilot study with immunoblots that utilized OspA as one of the scoring target antigens for detecting IgG and IgM antibodies to LDB in OspA-unvaccinated persons with Lyme disease symptoms yielded sensitivities and specificities of detection that were comparable to the CDC standard two-tier test for Lyme disease [21]. This evidence concerns the gene CD40LG and Lyme disease.